| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Puriblood Medical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$112.00 |
| 52 Week High | NT$134.00 |
| 52 Week Low | NT$104.50 |
| Beta | -0.061 |
| 11 Month Change | -0.44% |
| 3 Month Change | -3.45% |
| 1 Year Change | -13.85% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6847 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 3.2% | 2.8% | 4.6% |
| 1Y | -13.8% | 14.0% | 34.3% |
Return vs Industry: 6847 underperformed the TW Medical Equipment industry which returned 13.4% over the past year.
Return vs Market: 6847 underperformed the TW Market which returned 33.1% over the past year.
Price Volatility
| 6847 volatility | |
|---|---|
| 6847 Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.4% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6847 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6847's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 42 | Luke Chen | www.puriblood.com |
Puriblood Medical Co., Ltd. develops and sells blood cell separation products in Taiwan. The company offers leukocyte reduction filters for red blood cells, platelets, and whole blood, as well as real-time filtration sets for whole blood. It also offers Devin blood fractionation membrane filters and Minipuri cell screening syringe filters.
Puriblood Medical Co., Ltd. Fundamentals Summary
| 6847 fundamental statistics | |
|---|---|
| Market cap | NT$1.59b |
| Earnings (TTM) | -NT$51.59m |
| Revenue (TTM) | NT$125.27m |
12.7x
P/S Ratio-30.9x
P/E RatioIs 6847 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6847 income statement (TTM) | |
|---|---|
| Revenue | NT$125.27m |
| Cost of Revenue | NT$118.75m |
| Gross Profit | NT$6.52m |
| Other Expenses | NT$58.12m |
| Earnings | -NT$51.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.63 |
| Gross Margin | 5.21% |
| Net Profit Margin | -41.19% |
| Debt/Equity Ratio | 16.2% |
How did 6847 perform over the long term?
See historical performance and comparison